At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of lower urinary tract symptoms (LUTS)
- ✓Prostate volume 40–200 cc
- ✓Age ≥45 years
- ✓IPSS score ≥15
- ✕History of prostate or bladder cancer, pelvic radiation, untreated bladder stones, or findings suggestive of prostate cancer
- ✕Need for catheterization to relieve obstruction
- ✕Daily use of incontinence materials or padding
- ✕Neurogenic or hypotonic bladder, Parkinson's Disease, or uncontrolled diabetes
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
In Brief
A clinical study evaluating MRI Guided Transrectal Periuretheral Transitional Zone Ablation for BPH and 2 related conditions. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Over 100,000 BPH procedures are performed annually in the US. The purpose of this study is to evaluate the effectiveness of performing MRI guided transrectal laser ablation using a 980 nm laser (VisualaseTM by Medtronic, Inc., a Minnesota, U.S.A. company) to treat benign prostatic hypertrophy (BPH). The laser system will be used to necrotize urological soft tissue within the prostate under MRI guidance. This will be a single center, single arm prospective trial with an anticipated enrollment of 10 men. Patients who elect this treatment option and choose to be part of the study will be enrolled consecutively.
Study Details
Timeline
Interventions
Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.